共 3 条
[1]
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study
[J].
BREAST CANCER RESEARCH AND TREATMENT,
2012, 136 (02)
:503-511
Robertson, John F. R.
;
Lindemann, Justin P. O.
;
Llombart-Cussac, Antonio
;
Rolski, Janusz
;
Feltl, David
;
Dewar, John
;
Emerson, Laura
;
Dean, Andrew
;
Ellis, Matthew J.
.
[2]
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS; a randomised trial.[J].Christina Davies;Hongchao Pan;Jon Godwin;Richard Gray;Rodrigo Arriagada;Vinod Raina;Mirta Abraham;Victor Hugo Medeiros Alencar;Atef Badran;Xavier Bonfill;Joan Bradbury;Michael Clarke;Rory Collins;Susan R Davis;Antonella Delmestri;John F Forbes;Peiman Haddad;Ming-Feng Hou;Moshe Inbar;Hussein Khaled;Joanna Kielanowska;
[3]
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.[J].Meredith M Regan;Patrick Neven;Anita Giobbie-Hurder;Aron Goldhirsch;Bent Ejlertsen;Louis Mauriac;John F Forbes;Ian Smith;István Láng;Andrew Wardley;Manuela Rabaglio;Karen N Price;Richard D Gelber;Alan S Coates;Beat Thürlimann.Lancet Oncology.2011, 12